Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy.
about
Critical appraisal of eculizumab for atypical hemolytic uremic syndromePlasmapheresis Is Associated With Better Renal Outcomes in Lupus Nephritis Patients With Thrombotic Microangiopathy: A Case Series StudyAtypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to EculizumabComplement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab: A case report.HUS and atypical HUS.Two cases of atypical hemolytic uremic syndrome (aHUS) and eosinophilic granulomatosis with polyangiitis (EGPA): a possible relationship.Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab.Complement-mediated 'bystander' damage initiates host NLRP3 inflammasome activation.The complement system as a potential therapeutic target in rheumatic disease.Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence.Systemic lupus erythematosus biomarkers: the challenging quest.Many drugs for many targets: novel treatments for complement-mediated glomerular disease.Redefining lupus nephritis: clinical implications of pathophysiologic subtypes.Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.Eculizumab as rescue therapy in severe resistant lupus nephritis.Rapidly progressive IgA nephropathy: a form of vasculitis or a complement-mediated disease?Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum?Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.Anti-C1q autoantibodies as markers of renal involvement in childhood-onset systemic lupus erythematosus.Complement-mediated thrombotic microangiopathy associated with lupus nephritis
P2860
Q26750692-498FAF44-5064-4572-AF35-D25C712A1DDCQ33432006-7DAAD39A-5EBC-4A5C-8977-9EB641830372Q33436295-C33D9E86-72C9-4E6D-AE47-0DC9DBAA1E5EQ33439152-FCF3247C-BDEF-4ACD-8BCC-25ECBCF768A2Q33441069-72A55268-6F37-49E5-B3D5-2EF65ADC2E39Q33441880-6D8C7FC9-58E4-4C38-B1F7-1DAFB975DF43Q33705135-52517001-123A-4200-8F5B-A31E71C841AEQ36970884-A323D28B-E00A-4DB5-805C-CBFFE9304051Q38631542-24AB43C0-75ED-4295-AAE9-5E63327CFB3DQ38930294-B42CF3DE-DFFE-486C-99CD-83474E96F441Q39053118-F35BD283-9BAD-453C-91B9-4697995C3E1EQ39229285-B54AFB54-9740-4264-8453-95249707CEDDQ39410103-F9B0CAA5-B308-4F25-93BA-203214945310Q42086661-3BB5E175-5238-469C-BC74-A887E041BD77Q43177789-405FE355-6E54-46BD-A97C-0F5178FD2943Q43241462-826702B1-0982-4887-BBE0-A9A8ABF8C8CDQ43241467-ADBDCEC3-124B-4D28-89CC-80092DB0CC5CQ47640137-92FDDD2C-47BC-4F7B-B1FE-B7CB1097F466Q48361761-E94F9CBB-CA52-4FD1-B818-85D27A89BE2EQ58727886-69BA859E-6C66-49F0-B47A-47F1A096E387
P2860
Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Dramatic effects of eculizumab ...... stant to conventional therapy.
@en
Dramatic effects of eculizumab ...... stant to conventional therapy.
@nl
type
label
Dramatic effects of eculizumab ...... stant to conventional therapy.
@en
Dramatic effects of eculizumab ...... stant to conventional therapy.
@nl
prefLabel
Dramatic effects of eculizumab ...... stant to conventional therapy.
@en
Dramatic effects of eculizumab ...... stant to conventional therapy.
@nl
P2093
P2860
P1433
P1476
Dramatic effects of eculizumab ...... stant to conventional therapy.
@en
P2093
Alessandro Amore
Arrigo Schieppati
Inna Lastauka
Licia Peruzzi
Luca Vergano
Marina Noris
Rosanna Coppo
Silvana Martino
P2860
P2888
P304
P356
10.1007/S00467-014-2944-Y
P577
2014-08-31T00:00:00Z